SABCS 2020

Complete Coverage

Nivolumab-Abemaciclib-Endocrine Therapy Trial Stopped Due to Toxicity

Although the combination was deemed active in HR-positive, HER2-negative disease, findings don’t support further research.

Preoperative Pembrolizumab Plus Radiotherapy Found Active in TNBC

Combining neoadjuvant pembrolizumab with radiotherapy prior to standard of care chemotherapy may increase pathologic complete responses rates in TNBC.

Promising Outcomes With Lenvatinib Plus Pembrolizumab in Advanced TNBC

The majority of responses seen were ongoing at data cutoff.

Oncolytic Virus Primes an Immune Response in Breast Cancer

The oncolytic virus pelareorep may mediate priming of an adaptive immune response in women with early breast cancer.

Immune-Enriched Phenotype Linked to Improved TNBC Survival After AC

Improvements likely due to underlying genomic instability, increased sensitivity to DNA-damaging chemotherapy.

No Benefit to Single-Agent Pembrolizumab in Some With mTNBC Metastasized to Liver or Lung

Women with lung, liver metastases and high PD-L1 expression saw a survival benefit.

Salvage Neoadjuvant Chemo Induces “Very Low” Pathologic Complete Response Rate

The pathologic complete response rate was low following salvage neoadjuvant chemotherapy for patients with neoadjuvant endocrine therapy resistant disease.

Adjuvant Endocrine Therapy Alone Judged Suitable for Certain Breast Cancer Patients

Certain patients with luminal early breast cancer and up to 3 involved lymph nodes can be treated with adjuvant endocrine therapy alone.

Oral Chemo Combo Delays Disease Progression in Metastatic Breast Cancer

An oral chemotherapy combination delayed disease progression in patients with metastatic breast cancer, but came with added toxicity and unknown survival benefit.

Tool Estimates Risk of Distant Recurrence, Chemotherapy Benefit in Breast Cancer

A new online tool called RSClin was shown to estimate risk of distant recurrence and adjuvant chemotherapy benefit for patients with early breast cancer.

Women May Become Persistent Users of Controlled Substances After Mastectomy

Women who had a mastectomy with breast reconstruction for breast cancer treatment may be at risk for becoming dependent on opioids or sedative-hypnotic drugs.

No Added Treatment Burden for Neoadjuvant Atezolizumab, Say Investigators

Researchers said it was the first analysis “measuring the treatment burden of checkpoint inhibitor therapy for early-stage breast cancer using patient-reported outcomes.”

No Added Treatment Burden for Neoadjuvant Atezolizumab, Say Investigators

Researchers said it was the first analysis “measuring the treatment burden of checkpoint inhibitor therapy for early-stage breast cancer using patient-reported outcomes.”

Addition of Ipatasertib Confers No Benefit in Advanced Triple-Negative Breast Cancer

Adding ipatasertib to paclitaxel in those with PIK3CA/AKT1/PTEN-mutated advanced TNBC did not significantly improve PFS.

Physicians Commonly Miss Adverse Events in Patients With Breast Cancer

Compared with White patients, Black patients had a 92% increased odds of having adverse events underrecognized.

Pembrolizumab Benefits TNBC Regardless of Chemotherapy Backbone

The addition of pembrolizumab to chemotherapy benefited previously untreated patients with triple-negative breast cancer, regardless of chemotherapy regimen.

Select Postmenopausal Women With Breast Cancer May Forgo Adjuvant Chemotherapy

The addition of adjuvant chemotherapy to endocrine therapy may not benefit certain postmenopausal women with node-positive, early-stage breast cancer.

Immunostimulation May Boost Efficacy of Immunotherapy in Triple-Negative Breast Cancer

Preclinical evidence suggests that stimulating the immune system may bypass MYC and improve the efficacy of immunotherapy in triple-negative breast cancer.

Banned Breast Implants Not Linked to Recurrence, Death: A French Retrospective Analysis

Women who received silicone breast implants from Poly Implant Prothèse did not have an increased risk of breast cancer recurrence or early death, a retrospective study found.

Anastrozole vs Tamoxifen: Similar Outcomes, Different Toxicities

Long-term data showed that anastrozole and tamoxifen have similar efficacy in postmenopausal women with hormone receptor-positive DCIS, but toxicity profiles differed.